Tyramide Signal Amplification™ (TSA) is an patented* technology developed by PerkinElmer scientists that amplifies both chromogenic and Fluorescent signals in standard immunohistochemistry and in situ hybridization protocols, resulting in a significant increase in sensitivity, without loss of resolution or increase in background. Because TSA is a signal amplification technology, it eliminates the target amplification (PCR) sometimes utilized in in situ when low or single copy genes are present. By using TSA in immunohistochemistry applications, unamplified detection levels can be maintained while utilizing up to 1,000-fold less primary antibody.
Detection of p53 mRNA in Lung Tissue. Digoxigenin-labeled p53 RNA probes were hybridized to paraffin-embedded lung tissue. Comparison shows (A) standard digoxigenin detection with alkaline phophatase/BCIP-NBT (60 minute substrate incubation), and (B) TSA Plus with alkaline phosphatase/BCIP-NBT (15 minute substrate incubation).
The portfolio of TSA products have recently been expanded with the introduction of TSA Plus, a completely biotin-free system for chromogenic detection, and the TSA Cyanine 5 System, which combines the high fluorescence of cyanine dyes with the detection sensitivity of TSA technology. The new Cyanine 5 System join existing TSA kits containing other dyes, including Cyanine 3, thus offering multi-color detection capabilities in multiple-labeling applications
Biotin-Free TSA plus brings enhanced sensitivity to existing DIG labeling protocols.
Return to TSA Table of Contents
* TSA is protected by US patents: 5,731,158, 5,583,001, and 5,196,306 and foreign equivalents.